Female Genital Neoplasms

Subscribe to Selected New Research on Female Genital Neoplasms

71 relevant articles (2 outcomes, 4 trials/studies) found for this Disease

Description: Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).

Also Known As:

Genital Neoplasms, Female; Neoplasms, Female Genital; Neoplasms, Gynecologic; Female Genital Neoplasm; Genital Neoplasm, Female; Gynecologic Neoplasm; Neoplasm, Female Genital; Neoplasm, Gynecologic; Gynecologic Neoplasms

Relationship Network

Disease Context: Research Results

Neoplasms: 415397

Neoplasms by Site: 1

Urogenital Neoplasms: 178

Female Genital Neoplasms: 71

Uterine Neoplasms: 707

Vulvar Neoplasms: 253

Vaginal Neoplasms: 136

Fallopian Tube Neoplasms: 53

Female Urogenital Diseases and Pregnancy Complications

Female Urogenital Diseases

Urogenital Neoplasms: 178

Female Genital Neoplasms: 71

Ovarian Neoplasms: 13751

Uterine Neoplasms: 707

Vulvar Neoplasms: 253

Vaginal Neoplasms: 136

Fallopian Tube Neoplasms: 53

Related Diseases

1.	Neoplasms (Cancer)
2.	Carcinoma (Carcinomatosis)
3.	Endometrial Neoplasms (Endometrial Cancer)
4.	Leiomyoma (Uterine Fibroids)
5.	Female Genital Diseases

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Female Genital Neoplasms:

1.	Raloxifene (Evista)FDA Link 11/01/1996 - "These data indicate that SERMs such as raloxifene and tamoxifen act as estrogen antagonists in uterine myometrial cells and suggest that this class of compounds may be effective for treatment of this important gynecologic neoplasm." Order ALL the reference details at left...
2.	Selective Estrogen Receptor Modulators (SERM)IBA 11/01/1996 - "These data indicate that SERMs such as raloxifene and tamoxifen act as estrogen antagonists in uterine myometrial cells and suggest that this class of compounds may be effective for treatment of this important gynecologic neoplasm." Order ALL the reference details at left...
3.	Tamoxifen FDA LinkGeneric 11/01/1996 - "These data indicate that SERMs such as raloxifene and tamoxifen act as estrogen antagonists in uterine myometrial cells and suggest that this class of compounds may be effective for treatment of this important gynecologic neoplasm." Order ALL the reference details at left...
4.	Estrogen AntagonistsIBA 11/01/1996 - "These data indicate that SERMs such as raloxifene and tamoxifen act as estrogen antagonists in uterine myometrial cells and suggest that this class of compounds may be effective for treatment of this important gynecologic neoplasm." Order ALL the reference details at left...
5.	RadiumIBA 10/28/1971 - "[Studies with computers of the dosage distribution in the pelvis under intracavital radium treatment of gynecologic neoplasms]" 10/01/1973 - "[Colposcopy and colpocytology after radium treatment of gynecologic neoplasms]" 07/01/1964 - "[THE EFFECT OF COMBINED RADIUM-TELECOBALT IRRADIATION OF GYNECOLOGIC NEOPLASMS ON THE BLOOD COAGULATION SYSTEM.]" Order ALL the reference details at left...
6.	Estrogens (Estrogen)FDA Link 01/15/1980 - "The demonstration of estrogen receptor in malignant carcinoid tumor expands the spectrum of non-breast or non-gynecologic neoplasms that contain the receptor. " 12/04/1975 - "When estrogen use was adjusted for concomitant variables such as obesity, hypertension, diabetes, parity, referral pattern, age at diagnosis, year of diagnosis and other gynecologic neoplasms, the magnitude of the increased relative risk was associated with several of these variables, and was highest in patients without obesity and hypertension. " 12/04/1975 - "To determine the association between the incidence of endometrial cancer and the use of estrogen in menopausal and post-menopausal women, we retrospectively compared 317 patients with adenocarcinoma of the endometrium with an equal number of matched controls having other gynecologic neoplasms; 152 patients used estrogen, as compared to 54 of 317 controls. " 04/01/1987 - "A study of cytoplasmic and nuclear estrogen and progestin receptors in gynecologic neoplasms." Order ALL the reference details at left...
7.	Progesterone Receptors (Progesterone Receptor)IBA 04/01/1987 - "A study of cytoplasmic and nuclear estrogen and progestin receptors in gynecologic neoplasms." Order ALL the reference details at left...
8.	Hydroxyurea (Hydrea)FDA LinkGeneric 08/01/1964 - "PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: UROLOGIC AND GYNECOLOGIC NEOPLASMS." Order ALL the reference details at left...
9.	Biological Tumor Markers (Tumor Markers)IBA 09/01/1991 - "[Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K]" 03/01/1990 - "Tumor markers in gynecologic neoplasms." 07/01/1988 - "[The place of tumor markers in breast and gynecologic neoplasms]" 03/01/1990 - "The applications of tumor markers and steroid receptors in gynecologic neoplasms are described. " 07/20/1979 - "[T antigen and CEA; comparison between 2 tumor markers in breast cancer and malignant gynecologic neoplasms]" Order ALL the reference details at left...
10.	DNA (Deoxyribonucleic Acid)IBA 05/01/1991 - "[Clinical significance of the determination of cellular DNA content in gynecologic neoplasms]" 05/01/1981 - "The significance of nuclear DNA findings related to gynecologic neoplasms is discussed." 06/15/1969 - "Alterations in chromosomes and DNA content in gynecologic neoplasms." 01/01/1996 - "To establish a basis for the interpretation of DNA flow cytometric results of gynecologic neoplasms, paraffin blocks from 121 patients with a diagnosis of serous cystadenoma (n = 37), mucinous cystadenoma (n = 28), leiomyoma (n = 41), and fibrothecoma (n = 15), and normal tissue samples obtained from some of these patients, including ovary (n = 20), cervix (n = 20), and myometrium (n = 20) were analyzed for nuclear DNA content. " Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 07/01/1986 - "[Criteria for the determination of the immediate efficacy of chemotherapy in gynecologic neoplasms]" 03/17/1962 - "[Experimental studies on selective chemotherapy of gynecologic neoplasms.]" 07/25/1970 - "[Chemotherapy of malignant gynecologic neoplasms]" 08/31/1965 - "[Onco-chemotherapy by introduction into retzius space in treatment of female genital neoplasms]" 11/01/1992 - "[Intra-arterial infusion chemotherapy of female genital neoplasms]" Order ALL the reference details at left...
2.	Brachytherapy 10/01/1997 - "Intracavitary brachytherapy in the treatment of gynecologic neoplasms." 03/01/1991 - "[High dose brachytherapy in gynecologic neoplasms. " Order ALL the reference details at left...
3.	Aftercare (After-Treatment) 03/08/1979 - "[Clinical and urological after care in gynecologic neoplasms]" 06/10/1977 - "[Organization and realization of after-care examinations in cancer patients, especially with gynecologic neoplasms]" Order ALL the reference details at left...
4.	Dye Lasers 01/01/1985 - "Five patients with various gynecologic neoplasms were treated with photodynamic therapy using 630-nm light delivered from an argon dye laser system following the intravenous injection of hematoporphyrin derivative (HpD). " Order ALL the reference details at left...
5.	Transplantation (Transplant Recipients) 09/01/1977 - "[Transplantation of preserved bone marrow in complex treatment of gynecologic neoplasms]" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Female Genital Neoplasms

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>